The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The research target TLR10 (UniProt accession Q9BXR5) encodes human Toll-like receptor 10, a transmembrane glycoprotein belonging to the Toll-like receptor family (rodrigues2024tlr10anintriguing pages 1-2). TLR10 is the most recently identified member of the human TLR family and is unique among TLRs as it remains an "orphan receptor" with incompletely defined ligands and biological functions, making it the subject of ongoing investigation (rodrigues2024tlr10anintriguing pages 3-4, rodrigues2024tlr10anintriguing pages 2-3, rodrigues2024tlr10anintriguing pages 1-2). The gene is located on the same chromosomal cluster as TLR1 and TLR6, and shares substantial sequence homology with these receptors, indicating evolutionary relatedness within the TLR1 subfamily (su2021tlr10insightscontroversies pages 9-13, rodrigues2024tlr10anintriguing pages 3-4).
TLR10 functions primarily as an immunomodulatory pattern recognition receptor with context-dependent effects that can be either anti-inflammatory or, less commonly, pro-inflammatory (su2021tlr10insightscontroversies pages 27-30, fore2020tlr10andits pages 4-6, rodrigues2024tlr10anintriguing pages 2-3). Unlike most TLRs that predominantly activate inflammatory responses, TLR10 is characterized as a negative regulator of innate immune signaling, particularly of TLR2-driven responses (su2021tlr10insightscontroversies pages 27-30, su2021tlr10insightscontroversies pages 13-17). A landmark 2024 study by Deb and colleagues provided the first definitive evidence that TLR10 functions as an inhibitory receptor in human plasmacytoid dendritic cells (pDCs), where antibody-mediated engagement suppressed virus-induced production of type I and type III interferons as well as TNF-α without impairing viral uptake or pDC maturation (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 1-3).
As an orphan receptor, TLR10's natural ligand repertoire has not been definitively established, though multiple candidates have been proposed based on experimental evidence (su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 3-4). The most extensively studied proposed ligands include:
Nucleic acids: TLR10 has been reported to bind double-stranded RNA (dsRNA) in endosomal compartments at acidic pH, recruiting MyD88 and suppressing IRF7-dependent type I interferon production (su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 2-3). This endosomal nucleic acid recognition suggests a role in antiviral immunity regulation.
Bacterial lipopeptides: TLR10 appears to recognize or modulate responses to synthetic diacylated lipopeptides such as FSL-1 (typically a TLR2/TLR6 ligand) and triacylated lipopeptides like Pam3Cys and Pam3CSK4 (typically TLR2/TLR1 ligands), likely through formation of heterodimers with TLR2 (su2021tlr10insightscontroversies pages 27-30, rodrigues2024tlr10anintriguing pages 3-4, su2021tlr10insightscontroversies pages 13-17, su2021tlr10insightscontroversies pages 9-13). These ligands can enhance TLR2-TLR10 association and promote MyD88 recruitment.
Viral components: HIV-1 envelope glycoprotein gp41 and influenza virus-associated RNA-protein complexes have been identified as potential TLR10 activators, triggering NF-κB activation and inflammatory cytokine production in some experimental systems (su2021tlr10insightscontroversies pages 27-30, su2021tlr10insightscontroversies pages 5-9).
Bacterial pathogens: TLR10 has been implicated in responses to several bacterial species including Listeria monocytogenes, Helicobacter pylori, Borrelia burgdorferi, and Salmonella typhimurium, though the specific molecular patterns recognized remain undefined (su2021tlr10insightscontroversies pages 5-9, fore2020tlr10andits pages 4-6).
A comprehensive summary of proposed TLR10 ligands and their associated receptor complexes is provided in the following table:
| Ligand/PAMP or stimulus | Receptor complex | Cellular location | Reported biological effect |
|---|---|---|---|
| Viral double-stranded RNA (dsRNA) | TLR10 homodimer proposed; MyD88 recruited | Endosomal membrane | Direct binding has been reported in vitro under acidic conditions; associated with MyD88 recruitment and suppression of IRF7-dependent type-I interferon production. Its status as a physiological ligand remains provisional. (su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 2-3) |
| FSL-1, a synthetic diacylated lipopeptide | TLR2/TLR10 proposed; canonical comparator is TLR2/TLR6 | Primarily plasma membrane | TLR10 knockdown altered FSL-1-induced inflammatory outputs, including IL-8, IL-1, and CCL20. This establishes regulatory involvement but not definitive direct binding by TLR10. (su2021tlr10insightscontroversies pages 27-30, rodrigues2024tlr10anintriguing pages 5-5) |
| Pam3Cys/Pam3CSK4, synthetic triacylated lipopeptides | TLR2/TLR10 heterodimer proposed; canonical comparator is TLR2/TLR1 | Plasma membrane | Pam3CSK4 enhances TLR2–TLR10 association and can promote MyD88 recruitment; TLR10 has also reduced Pam3Cys-induced IL-8 in some systems, consistent with context-dependent modulation of TLR2 signaling. (su2021tlr10insightscontroversies pages 13-17, su2021tlr10insightscontroversies pages 9-13, fore2020tlr10andits pages 4-6) |
| Lipopolysaccharide (LPS) | TLR2/TLR10 proposed in some pathogen contexts; experimentally linked to TLR4–TLR10 trafficking/crosstalk | Plasma membrane followed by cytoplasmic vesicles or early endosomes | LPS induces TLR10 internalization in neutrophils and regulates its expression through TLR4, ROS, and NF-κB. Knockdown or antibody studies show altered cytokine release, but LPS is not established as a direct TLR10 ligand. (rodrigues2024tlr10anintriguing pages 5-5) |
| Flagellin | TLR10-containing complex proposed; partner not resolved | Presumed plasma membrane | Flagellin-responsive cytokines decrease after TLR10 knockdown in some human cell systems, suggesting regulatory participation; direct recognition and receptor stoichiometry remain unproven. (su2021tlr10insightscontroversies pages 27-30, rodrigues2024tlr10anintriguing pages 3-4, rodrigues2024tlr10anintriguing pages 5-5) |
| HIV-1 gp41 | TLR10-containing complex; exact dimer partner unresolved | Plasma membrane proposed | Reported to trigger TLR10-associated NF-κB activation and IL-8 production. Direct ligand specificity and the required receptor partner need further validation. (su2021tlr10insightscontroversies pages 27-30, su2021tlr10insightscontroversies pages 5-9) |
| Influenza A virus components or viral RNA–protein complexes | TLR10-containing complex; TLR2 cooperation proposed in some reports | Cell surface and/or endosomal compartments | TLR10 loss-of-function weakens some influenza-induced inflammatory responses, whereas endosomal TLR10 may regulate nucleic-acid signaling. The exact viral molecular ligand is unresolved. (su2021tlr10insightscontroversies pages 5-9, su2021tlr10insightscontroversies pages 17-21) |
| Listeria monocytogenes PAMPs | TLR2/TLR10 heterodimer proposed | Plasma membrane of epithelial or myeloid cells | TLR10 can promote CCL20 and IL-8 production and host defense in some models; silencing increased bacterial viability. Other systems support broader inhibitory effects, indicating cell-context dependence. (su2021tlr10insightscontroversies pages 5-9, fore2020tlr10andits pages 4-6, su2021tlr10insightscontroversies pages 30-31) |
| Helicobacter pylori components, including atypical LPS-associated stimuli | TLR2/TLR10 heterodimer proposed | Plasma membrane of gastric epithelial and immune cells | Reported to enhance NF-κB-associated inflammatory signaling in gastric-cell models, although TLR10 can also restrain TLR2 responses. Direct binding to a chemically defined H. pylori ligand has not been firmly established. (su2021tlr10insightscontroversies pages 5-9, fore2020tlr10andits pages 4-6) |
| Borrelia burgdorferi PAMPs | TLR2/TLR10 proposed | Plasma membrane | TLR10 engagement or expression has been associated with altered inflammatory cytokine production in response to B. burgdorferi. The responsible microbial molecule and direct binding mechanism remain unresolved. (fore2020tlr10andits pages 4-6, su2021tlr10insightscontroversies pages 5-9) |
Table: Summary of candidate TLR10 ligands or stimuli, proposed dimer partners, sites of action, and reported immune effects. Most assignments remain provisional because no endogenous ligand–receptor pair has been definitively validated.
TLR10 exhibits dual subcellular localization, functioning at both the plasma membrane and in endosomal compartments (rodrigues2024tlr10anintriguing pages 2-3, su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 3-4). This distinguishes it from the strictly cell-surface TLRs (TLR1, TLR2, TLR4, TLR5, TLR6) and the exclusively endosomal TLRs (TLR3, TLR7, TLR8, TLR9) (fore2020tlr10andits pages 1-2, rodrigues2024tlr10anintriguing pages 1-2).
At the plasma membrane, TLR10 is constitutively expressed as a type I transmembrane protein with its leucine-rich repeat ectodomain exposed extracellularly for ligand recognition and its Toll/interleukin-1 receptor (TIR) domain positioned intracellularly for signaling (rodrigues2024tlr10anintriguing pages 1-2, su2021tlr10insightscontroversies pages 13-17, fore2020tlr10andits pages 2-4). Studies in human neutrophils have demonstrated dynamic trafficking: following LPS stimulation, TLR10 undergoes ligand-induced endocytosis, moving from the plasma membrane into cytoplasmic vesicles within approximately 60-90 minutes, colocalizing with flotillin-1 (a lipid raft marker) and EEA-1 (an early endosomal marker), before returning to the cell surface after approximately 2 hours (rodrigues2024tlr10anintriguing pages 5-5).
In endosomal compartments, TLR10 has been shown to recognize pathogen nucleic acids, particularly dsRNA, and recruit MyD88 for signal transduction (rodrigues2024tlr10anintriguing pages 2-3, su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 3-4). This endosomal localization may enable TLR10 to regulate responses to internalized viral particles or nucleic acids derived from phagocytosed pathogens.
TLR10 expression exhibits remarkable cell-type specificity within the immune system. Among human immune cells, expression is highest in B cells and plasmacytoid dendritic cells (pDCs), with detectable expression also in eosinophils, neutrophils, monocytes, and regulatory T cells (Tregs) (su2021tlr10insightscontroversies pages 5-9, fore2020tlr10andits pages 2-4, rodrigues2024tlr10anintriguing pages 3-4). Notably, monocytes, natural killer cells, and conventional T cells reportedly lack detectable TLR10 expression (su2021tlr10insightscontroversies pages 5-9). TLR10 is also expressed in non-immune cells including trophoblasts and various epithelial cell types (fore2020tlr10andits pages 2-4). At the tissue level, TLR10 is found primarily in lymphoid organs including lymph nodes, thymus, tonsils, and spleen (rodrigues2024tlr10anintriguing pages 3-4).
TLR10 engages a complex, context-dependent network of signaling pathways that can result in either immune suppression or activation depending on the cellular environment, receptor dimerization partner, and ligand (su2021tlr10insightscontroversies pages 9-13, su2021tlr10insightscontroversies pages 5-9). Recent mechanistic advances, particularly the 2024 study by Deb et al., have clarified several key pathways.
STAT3-SOCS3-IRF7 Axis (Primary Inhibitory Pathway in pDCs): The most clearly defined inhibitory mechanism was established in 2024 through studies of primary human plasmacytoid dendritic cells (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 1-3, deb2024tlr10(cd290)is pages 10-12). Antibody-mediated engagement of surface TLR10 induces rapid phosphorylation of STAT3 (within approximately 1 hour) through an as-yet-unidentified kinase, without affecting phosphorylation of NF-κB, STAT1, or Akt (deb2024tlr10(cd290)is pages 8-10). This STAT3 activation leads to selective induction of the suppressor of cytokine signaling 3 (SOCS3), a negative feedback regulator (deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 10-12, deb2024tlr10(cd290)is pages 20-27). The functional consequence is potent inhibition of IRF7 nuclear translocation, without preventing IRF7 phosphorylation, thereby selectively suppressing type I interferon (IFN-α) and type III interferon (IFN-λ) production as well as TNF-α secretion in response to viral stimulation (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 10-12). Importantly, this inhibitory effect does not impair viral uptake, pDC maturation marker expression (CD40, CD80, CD83, CD86), NF-κB nuclear translocation, or the capacity of pDCs to stimulate allogeneic T cells, indicating pathway-selective rather than global immunosuppression (deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 20-27).
MyD88-Dependent Pathways: TLR10 homodimers and TLR2/TLR10 heterodimers can recruit the adaptor protein MyD88 and its partner TIRAP/MAL through interactions involving the TIR domain BB loop (su2021tlr10insightscontroversies pages 9-13, fore2020tlr10andits pages 2-4). However, unlike canonical activating TLR complexes, TLR10-MyD88 signaling can result in inhibition of downstream NF-κB and MAPK pathways rather than their activation (fore2020tlr10andits pages 4-6, fore2020tlr10andits pages 2-4). The mechanism involves either direct inhibition of MyD88 signaling, competitive interference with TLR2 dimerization and ligand binding, or recruitment of distinct adaptor proteins that redirect signaling outcomes (su2021tlr10insightscontroversies pages 13-17).
NF-κB and MAPK Modulation: TLR10 can suppress NF-κB activation by inhibiting IκB degradation and reducing phosphorylation of the p65 subunit (fore2020tlr10andits pages 2-4, su2021tlr10insightscontroversies pages 13-17, rodrigues2024tlr10anintriguing pages 5-5). Similarly, TLR10 engagement can reduce phosphorylation of MAPK family members including p38, ERK, and JNK, thereby limiting transcription of pro-inflammatory genes (fore2020tlr10andits pages 4-6, fore2020tlr10andits pages 2-4, su2021tlr10insightscontroversies pages 27-30). Functional evidence comes from experiments showing that TLR10 blockade or knockdown increases inflammatory cytokine production, while TLR10 engagement or overexpression suppresses these outputs in multiple cell types (su2021tlr10insightscontroversies pages 13-17, rodrigues2024tlr10anintriguing pages 5-5).
PI3K/Akt-IL-1Ra Pathway: TLR10 activation can engage PI3K/Akt signaling to induce production of interleukin-1 receptor antagonist (IL-1Ra), an endogenous anti-inflammatory cytokine that blocks IL-1β activity (su2021tlr10insightscontroversies pages 13-17, su2021tlr10insightscontroversies pages 27-30). This mechanism provides an additional layer of anti-inflammatory control by shifting the cytokine balance toward immune suppression.
While TLR10 functions predominantly as an inhibitory receptor, certain experimental contexts reveal pro-inflammatory capabilities (su2021tlr10insightscontroversies pages 5-9, su2021tlr10insightscontroversies pages 17-21). Engineered chimeric receptors containing TLR10 cytoplasmic domains can activate NF-κB and induce TNF-α, IL-6, AP-1, and IL-4 expression (su2021tlr10insightscontroversies pages 5-9). In infection models, TLR10 knockdown reduced pro-inflammatory cytokine expression in response to TLR ligands and influenza virus, suggesting that endogenous TLR10 can contribute to inflammatory responses in specific cellular and pathogen contexts (su2021tlr10insightscontroversies pages 5-9, su2021tlr10insightscontroversies pages 17-21). During Listeria monocytogenes infection, TLR10 increased production of CCL20 and IL-8, supporting host defense (su2021tlr10insightscontroversies pages 5-9).
A comprehensive summary of TLR10 signaling pathways is provided in the following table:
| Signaling component or pathway | Mechanism of action | Cellular outcome | Key evidence |
|---|---|---|---|
| MyD88 recruitment | TLR10 homodimers and proposed TLR2/TLR10 heterodimers recruit MyD88 through cytoplasmic TIR-domain interactions. Endosomal dsRNA-associated TLR10 reportedly recruits MyD88 rather than TRIF. | Context-dependent: may support IRAK–TRAF6 inflammatory signaling or inhibit NF-κB and MAPK activity. | Direct association with MyD88 and TIRAP has been reported; dominant-negative MyD88 blocks TLR10-associated ENA-78 expression. Signaling downstream of endogenous TLR10 remains incompletely resolved. (su2021tlr10insightscontroversies pages 9-13, fore2020tlr10andits pages 2-4) |
| STAT3–SOCS3 inhibitory axis | Antibody-mediated engagement of surface TLR10 in human plasmacytoid dendritic cells increases STAT3 phosphorylation and selectively induces SOCS3; the upstream kinase is unknown. | Suppresses IFN-α, IFN-λ, and TNF-α without impairing viral uptake, maturation markers, or T-cell stimulation. | Primary human pDC experiments detected STAT3 phosphorylation and SOCS3 induction within approximately one hour; NF-κB, STAT1, and Akt phosphorylation were unaffected. (deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 10-12, deb2024tlr10(cd290)is pages 27-27) |
| IRF7 inhibition | TLR10 engagement inhibits IRF7 nuclear translocation after viral stimulation without substantially preventing IRF7 phosphorylation. | Selectively suppresses IRF7-dependent type-I and type-III interferon responses in pDCs. | Anti-TLR10 engagement reduced virus-induced cytokines and IRF7 nuclear entry while leaving NF-κB nuclear translocation and viral uptake intact. The proposed STAT3/SOCS3-to-IRF7 causal chain is not yet fully proven. (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 10-12, deb2024tlr10(cd290)is pages 20-27) |
| NF-κB modulation | TLR10 can inhibit IκB degradation and NF-κB activation, potentially through competition for TLR2 ligands or partners or recruitment of inhibitory adaptors. Engineered receptors and selected infection models instead show activation. | In inhibitory settings, lowers IL-1β, IL-6, IL-8, and TNF-α; in activating settings, increases IL-8, CCL20, and other inflammatory mediators. | TLR10 blockade or depletion increases phospho-p65 and cytokines in some systems but decreases ligand-induced cytokines in others, demonstrating dependence on cell type, ligand, and receptor configuration. (su2021tlr10insightscontroversies pages 5-9, fore2020tlr10andits pages 2-4, su2021tlr10insightscontroversies pages 13-17, rodrigues2024tlr10anintriguing pages 5-5) |
| MAPK pathways: p38, ERK, and JNK | TLR10-containing complexes can reduce p38, ERK, and JNK phosphorylation downstream of TLR2/MyD88; other contexts permit MAPK-associated activation. | Predominantly limits transcription of proinflammatory mediators, although activating effects occur in some pathogen and cell contexts. | Antibody, receptor-expression, and ligand-response experiments support MAPK suppression, but the direct biochemical target and relative contribution of each kinase remain unresolved. (fore2020tlr10andits pages 4-6, fore2020tlr10andits pages 2-4, su2021tlr10insightscontroversies pages 27-30) |
| PI3K/Akt | TLR10 engagement is linked to PI3K/Akt-dependent induction of IL-1 receptor antagonist; some inhibitory models also show reduced Akt phosphorylation. | Promotes an anti-inflammatory cytokine balance by increasing IL-1Ra and opposing IL-1β activity. | Pharmacologic and cellular evidence supports PI3K/Akt involvement in IL-1Ra induction, although pathway direction varies among experimental systems. (su2021tlr10insightscontroversies pages 13-17, su2021tlr10insightscontroversies pages 27-30) |
| IRAK–TRAF6–AP-1 cascade | In an activating configuration, MyD88/TIRAP recruitment may engage IRAK1, IRAK4, and TRAF6, followed by AP-1 and NF-κB activation. | Potentially induces TNF-α, IL-1, IL-6, IL-12, IL-18, ENA-78, and related inflammatory genes. | Much of the activating evidence comes from chimeric or engineered TLR10 constructs and selected infection models; support is less definitive for endogenous TLR10. (su2021tlr10insightscontroversies pages 9-13, su2021tlr10insightscontroversies pages 5-9) |
| Cytokine and chemokine regulation | TLR10 integrates MyD88, STAT3/SOCS3, IRF7, NF-κB, MAPK, and PI3K/Akt signaling. Output depends on ligand, dimer partner, compartment, and cell type. | Inhibitory profile: lower IFN-α, IFN-λ, TNF-α, IL-1β, IL-6, and IL-8 with higher IL-1Ra or IL-10. Activating profile: increased IL-8, CCL20, IL-6, or TNF-α. | Primary pDC evidence strongly supports selective antiviral suppression, whereas monocyte, epithelial-cell, overexpression, knockdown, and antibody studies show mixed pro- and anti-inflammatory effects. (su2021tlr10insightscontroversies pages 27-30, deb2024tlr10(cd290)is pages 15-20, rodrigues2024tlr10anintriguing pages 5-5) |
Table: Summary of the principal activating and inhibitory pathways attributed to human TLR10. The table distinguishes strong primary-cell evidence from context-dependent or incompletely resolved signaling models.
TLR10 functions through formation of both homodimers and heterodimers, particularly with TLR1 and TLR2 (su2021tlr10insightscontroversies pages 13-17, rodrigues2024tlr10anintriguing pages 7-7, su2021tlr10insightscontroversies pages 9-13, rodrigues2024tlr10anintriguing pages 3-4). This dimerization capacity is critical for ligand recognition and determines signaling outcomes.
Structural Organization: TLR10 contains three functional domains: (1) an extracellular leucine-rich repeat (LRR) domain responsible for ligand recognition and receptor dimerization, (2) a single-pass transmembrane region that mediates homodimerization and heterodimerization through extensive interactions with corresponding domains of TLR1 and TLR6, and (3) an intracellular TIR domain consisting of five parallel β-sheets surrounded by five α-helical segments that recruits adaptor proteins (rodrigues2024tlr10anintriguing pages 3-4, su2021tlr10insightscontroversies pages 13-17). Structural studies have demonstrated that the isolated TLR10 TIR domain forms symmetric homodimers, and the full ectodomain also assembles into stable homodimers (su2021tlr10insightscontroversies pages 13-17).
Heterodimerization: TLR10 exhibits approximately 87% of its homodimer affinity for TLR1, while the TLR1/TLR2 heterodimer shows approximately 80% relative affinity, indicating that TLR10 can compete effectively for TLR1 and potentially disrupt TLR1/TLR2 signaling (su2021tlr10insightscontroversies pages 9-13). TLR2/TLR10 association is enhanced by lipidated ligands such as Pam3CSK4 and depends primarily on the TLR10 ectodomain (su2021tlr10insightscontroversies pages 9-13). Domain-swap experiments have shown that the TLR10 ectodomain and transmembrane region support interaction with TLR2, while the TIR domain determines downstream signaling: replacing the TLR1 TIR domain with the TLR10 TIR domain abolishes strong inflammatory responses, demonstrating that TIR-domain-specific adaptor recruitment is critical for functional outcomes (su2021tlr10insightscontroversies pages 13-17).
Functional Consequences: The nature of the receptor complex—TLR10 homodimer versus TLR10/TLR1 or TLR10/TLR2 heterodimer—determines biological outcomes. TLR10 homodimers and TLR10/TLR1 heterodimers are generally associated with pro-inflammatory activity, whereas TLR2/TLR10 heterodimers show variable effects ranging from enhanced to inhibited TLR2 signaling depending on experimental conditions (rodrigues2024tlr10anintriguing pages 7-7, rodrigues2024tlr10anintriguing pages 3-4). This heterogeneity reflects competition for ligands, differential adaptor recruitment, and cell-type-specific co-receptor availability.
Plasmacytoid Dendritic Cells: The 2024 study by Deb et al. established that TLR10 regulates pDC antiviral responses by suppressing type I and type III interferon production through the STAT3-SOCS3-IRF7 pathway, while preserving the ability of pDCs to stimulate T cells (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 1-3, deb2024tlr10(cd290)is pages 10-12). This selective inhibition positions TLR10 as a critical brake on pDC-mediated interferon responses, which is significant because excessive pDC activation and interferon production are implicated in autoimmune diseases such as systemic lupus erythematosus and type I interferon-driven inflammatory conditions.
B Cells: TLR10 expression in B cells is dynamic, increasing during activation and maturation, and may function to restrain B cell activation and autoantibody production (rodrigues2024tlr10anintriguing pages 3-4, rodrigues2024tlr10anintriguing pages 4-5). In rheumatoid arthritis, pro-inflammatory B cell subsets express lower TLR10 than anti-inflammatory subsets, consistent with a protective, inflammation-limiting role (su2021tlr10insightscontroversies pages 13-17). Conversely, reduced TLR10 expression in B cell subsets from patients with primary Sjögren's syndrome correlates with high disease activity, potentially indicating loss of inhibitory control (rodrigues2024tlr10anintriguing pages 4-5).
Neutrophils: In human neutrophils, TLR10 expression is regulated by reactive oxygen species, TLR4 signaling, and NF-κB, with evidence that TLR10 undergoes dynamic trafficking in response to inflammatory stimuli and may regulate neutrophil chemotaxis (rodrigues2024tlr10anintriguing pages 5-5).
Regulatory T Cells: TLR10 expression on regulatory T cells (Tregs) is controlled by FOXP3, a master regulator of Treg function, suggesting specialized immunoregulatory roles distinct from other TLRs (rodrigues2024tlr10anintriguing pages 4-5, fore2020tlr10andits pages 2-4).
TLR10 genetic polymorphisms have been associated with susceptibility to, or protection from, a broad spectrum of human diseases (fore2020tlr10andits pages 6-7, su2021tlr10insightscontroversies pages 17-21, fore2020tlr10andits pages 9-10, su2021tlr10insightscontroversies pages 30-31):
Autoimmune Diseases: Variants including rs4129009, rs11096955, rs11096957, and rs10004195 are associated with rheumatoid arthritis, Crohn's disease, autoimmune thyroid disease (including Graves' disease and Hashimoto's thyroiditis), primary Sjögren's syndrome, and IgA nephropathy (fore2020tlr10andits pages 6-7, su2021tlr10insightscontroversies pages 17-21, rodrigues2024tlr10anintriguing pages 4-5, fore2020tlr10andits pages 9-10). The functional variant I437T alters TNF-α-induced NF-κB transcription and may predict worse prognosis in rheumatoid arthritis (fore2020tlr10andits pages 6-7).
Infectious Diseases: TLR10 polymorphisms influence susceptibility to tuberculosis (rs11096957), complicated skin and skin-structure infections (I775L and I369L variants show protective effects), Helicobacter pylori-associated gastritis (rs10004195), Crimean-Congo hemorrhagic fever, asthma following bronchiolitis (rs4129009), and responses to influenza and HIV infection (fore2020tlr10andits pages 6-7, su2021tlr10insightscontroversies pages 17-21, su2021tlr10insightscontroversies pages 13-17, su2021tlr10insightscontroversies pages 30-31).
Cancer: TLR10 genetic variants are associated with urothelial bladder cancer, nasopharyngeal carcinoma, prostate cancer (rs11096955 and rs11096957 associated with reduced risk), papillary thyroid carcinoma, and non-Hodgkin lymphoma (fore2020tlr10andits pages 6-7, su2021tlr10insightscontroversies pages 17-21).
Metabolic Disease: Human TLR10 transgenic mice fed a high-fat diet showed smaller adipocytes, reduced adipose tissue mass, and marginally lower plasma insulin, implicating TLR10 in obesity-related inflammation and metabolic regulation (su2021tlr10insightscontroversies pages 13-17).
TLR10 is emerging as a promising therapeutic target for immune-mediated and inflammatory diseases (deb2024tlr10(cd290)is pages 1-3, fore2020tlr10andits pages 6-7, fore2020tlr10andits pages 4-6, rodrigues2024tlr10anintriguing pages 4-5):
Antibody-Mediated Targeting: Monoclonal antibodies that engage TLR10 can suppress pro-inflammatory cytokine production, reduce dendritic cell capacity to activate T cells, and modulate monocyte differentiation (rodrigues2024tlr10anintriguing pages 5-5, rodrigues2024tlr10anintriguing pages 4-5). The 2024 pDC study proposed antibody-mediated TLR10 engagement as a selective therapeutic strategy for autoimmune diseases characterized by aberrant pDC activation and type I interferon production, potentially avoiding generalized immunosuppression due to TLR10's restricted expression in B cells, monocytes, and pDCs (deb2024tlr10(cd290)is pages 1-3, deb2024tlr10(cd290)is pages 12-13).
Experimental Models: Human TLR10 knock-in/transgenic mice have been developed by inserting the human TLR10 open reading frame into the ROSA26 locus or using CMV-FLAG-TLR10 constructs, providing in vivo platforms for studying TLR10 function and evaluating therapeutic interventions (su2021tlr10insightscontroversies pages 21-23, su2021tlr10insightscontroversies pages 17-21, rodrigues2024tlr10anintriguing pages 6-7). These models demonstrate that TLR10 functions primarily as an inhibitor of TLR2-driven signaling in vivo, although engagement can also up-regulate distinct gene sets (su2021tlr10insightscontroversies pages 21-23, su2021tlr10insightscontroversies pages 17-21).
Mechanistic Approaches: Experimental strategies to study TLR10 include antibody-mediated receptor engagement, siRNA-mediated knockdown in human cell lines, expression analysis in patient samples, in vitro ligand-binding assays, receptor chimera construction, and functional assays measuring cytokine production and signaling pathway activation (rodrigues2024tlr10anintriguing pages 5-5, fore2020tlr10andits pages 2-4, su2021tlr10insightscontroversies pages 21-23, su2021tlr10insightscontroversies pages 17-21, su2021tlr10insightscontroversies pages 13-17, rodrigues2024tlr10anintriguing pages 4-5).
Clinical Applications Under Investigation: Potential therapeutic approaches include: (1) enhancing TLR10 anti-inflammatory activity to suppress NF-κB and inflammatory cytokine production in rheumatoid arthritis and other hyperinflammatory autoimmune conditions, (2) promoting M2 macrophage/microglial polarization for neuroprotective applications, (3) using TLR10 polymorphisms for disease risk stratification and prognostic assessment, and (4) modulating TLR10 expression or signaling pathways through vitamin D or other upstream regulators (fore2020tlr10andits pages 6-7, fore2020tlr10andits pages 4-6, fore2020tlr10andits pages 9-10).
The characterization of TLR10 function represents an evolving field with several important caveats. TLR10 remains an orphan receptor with no definitively validated endogenous ligand, and many proposed ligand-receptor interactions are based on indirect evidence from knockdown, overexpression, or antibody-engagement experiments rather than direct biochemical binding studies (su2021tlr10insightscontroversies pages 5-9, rodrigues2024tlr10anintriguing pages 3-4, rodrigues2024tlr10anintriguing pages 2-3, rodrigues2024tlr10anintriguing pages 1-2). The conflicting reports of pro-inflammatory versus anti-inflammatory activity reflect genuine context-dependence—varying by cell type, ligand, receptor dimerization partner, and subcellular compartment—rather than experimental artifact (fore2020tlr10andits pages 4-6, rodrigues2024tlr10anintriguing pages 2-3, su2021tlr10insightscontroversies pages 1-5).
The strongest mechanistic evidence comes from the 2024 study by Deb et al. in primary human plasmacytoid dendritic cells, which used antibody-mediated engagement, phospho-flow cytometry, gene expression analysis, nuclear translocation assays, and functional cytokine measurements to establish the STAT3-SOCS3-IRF7 inhibitory axis (deb2024tlr10(cd290)is pages 15-20, deb2024tlr10(cd290)is pages 8-10, deb2024tlr10(cd290)is pages 1-3, deb2024tlr10(cd290)is pages 10-12). This represents the first definitive characterization of a TLR10-specific signaling mechanism in primary human immune cells. Earlier evidence derives largely from cell-line overexpression systems, knockdown experiments, and TLR10 transgenic mice, which provide valuable but more indirect support (su2021tlr10insightscontroversies pages 21-23, su2021tlr10insightscontroversies pages 17-21, su2021tlr10insightscontroversies pages 13-17).
A major impediment to TLR10 research is the absence of a functional TLR10 gene in mice—the most widely used model organism for immunology research—necessitating reliance on human cell systems, TLR10 knock-in mice, or alternative species such as rats that naturally express TLR10 (fore2020tlr10andits pages 2-4, rodrigues2024tlr10anintriguing pages 6-7).
TLR10 (CD290) is a unique member of the human Toll-like receptor family that functions primarily as an immunomodulatory pattern recognition receptor with predominantly anti-inflammatory effects. It is localized at both the plasma membrane and in endosomal compartments, with highest expression in B cells and plasmacytoid dendritic cells. TLR10 can form homodimers or heterodimers with TLR1 and TLR2, and while its natural ligand repertoire remains incompletely defined, proposed ligands include double-stranded RNA, bacterial lipopeptides, viral envelope proteins, and components of various bacterial pathogens.
The primary signaling mechanism involves recruitment of MyD88 adaptor proteins, with a recently elucidated inhibitory pathway in plasmacytoid dendritic cells operating through STAT3 phosphorylation, SOCS3 induction, and suppression of IRF7 nuclear translocation to limit type I and type III interferon production. Additional regulatory pathways include modulation of NF-κB, MAPK (p38, ERK, JNK), and PI3K/Akt signaling. TLR10 genetic polymorphisms are associated with susceptibility to autoimmune diseases, infections, and cancers, and the receptor represents a promising therapeutic target for conditions characterized by excessive inflammation or aberrant interferon production.
Future research priorities include: (1) definitive identification of endogenous TLR10 ligands through biochemical binding studies, (2) clarification of the molecular mechanisms governing pro- versus anti-inflammatory signaling, (3) structural determination of TLR10 homodimers and heterodimers with ligands bound, (4) preclinical evaluation of TLR10-targeting therapeutics in disease models, and (5) clinical translation of TLR10 genetic variants as biomarkers and TLR10-directed therapies for autoimmune and inflammatory conditions.
References
(rodrigues2024tlr10anintriguing pages 1-2): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 3-4): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 2-3): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(su2021tlr10insightscontroversies pages 9-13): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(su2021tlr10insightscontroversies pages 27-30): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(fore2020tlr10andits pages 4-6): Faith Fore, Cut Indriputri, Janet Mamutse, and Jusak Nugraha. Tlr10 and its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Network, Apr 2020. URL: https://doi.org/10.4110/in.2020.20.e21, doi:10.4110/in.2020.20.e21. This article has 141 citations.
(su2021tlr10insightscontroversies pages 13-17): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(deb2024tlr10(cd290)is pages 15-20): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(deb2024tlr10(cd290)is pages 1-3): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(su2021tlr10insightscontroversies pages 5-9): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 5-5): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(su2021tlr10insightscontroversies pages 17-21): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(su2021tlr10insightscontroversies pages 30-31): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(fore2020tlr10andits pages 1-2): Faith Fore, Cut Indriputri, Janet Mamutse, and Jusak Nugraha. Tlr10 and its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Network, Apr 2020. URL: https://doi.org/10.4110/in.2020.20.e21, doi:10.4110/in.2020.20.e21. This article has 141 citations.
(fore2020tlr10andits pages 2-4): Faith Fore, Cut Indriputri, Janet Mamutse, and Jusak Nugraha. Tlr10 and its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Network, Apr 2020. URL: https://doi.org/10.4110/in.2020.20.e21, doi:10.4110/in.2020.20.e21. This article has 141 citations.
(deb2024tlr10(cd290)is pages 8-10): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(deb2024tlr10(cd290)is pages 10-12): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(deb2024tlr10(cd290)is pages 20-27): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(deb2024tlr10(cd290)is pages 27-27): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 7-7): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 4-5): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(fore2020tlr10andits pages 6-7): Faith Fore, Cut Indriputri, Janet Mamutse, and Jusak Nugraha. Tlr10 and its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Network, Apr 2020. URL: https://doi.org/10.4110/in.2020.20.e21, doi:10.4110/in.2020.20.e21. This article has 141 citations.
(fore2020tlr10andits pages 9-10): Faith Fore, Cut Indriputri, Janet Mamutse, and Jusak Nugraha. Tlr10 and its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Network, Apr 2020. URL: https://doi.org/10.4110/in.2020.20.e21, doi:10.4110/in.2020.20.e21. This article has 141 citations.
(deb2024tlr10(cd290)is pages 12-13): Pratik Deb, Sukhwinder Singh, Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, and Patricia Fitzgerald-Bocarsly. Tlr10 (cd290) is a regulator of immune responses in human plasmacytoid dendritic cells. Journal of immunology, 213:577-587, Jul 2024. URL: https://doi.org/10.4049/jimmunol.2200468, doi:10.4049/jimmunol.2200468. This article has 10 citations and is from a domain leading peer-reviewed journal.
(su2021tlr10insightscontroversies pages 21-23): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.
(rodrigues2024tlr10anintriguing pages 6-7): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(su2021tlr10insightscontroversies pages 1-5): Si‐Biao Su, Lin Tao, Ze‐Ping Deng, Wen Chen, Shan‐Yu Qin, and Hai‐Xing Jiang. Tlr10: insights, controversies and potential utility as a therapeutic target. Scandinavian Journal of Immunology, Oct 2021. URL: https://doi.org/10.1111/sji.12988, doi:10.1111/sji.12988. This article has 88 citations and is from a peer-reviewed journal.